Benjamin Weide

Summary

Country: Germany

Publications

  1. doi request reprint Immunologic correlates in the course of treatment with immunomodulating antibodies
    Benjamin Weide
    Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Germany Electronic address
    Semin Oncol 42:448-58. 2015
  2. doi request reprint Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses
    Benjamin Weide
    Authors Affiliations Departments of Dermatology, Center of Dermato Oncology and
    Cancer Immunol Res 2:668-78. 2014
  3. pmc Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour
    Benjamin Weide
    Center for Dermatooncology, Department of Dermatology, University Medical Center, Tuebingen, Germany
    PLoS ONE 8:e66953. 2013
  4. pmc Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis
    Benjamin Weide
    Department of Dermatology, University Medical Center, Tubingen, Germany
    PLoS ONE 8:e63137. 2013
  5. pmc Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
    B Weide
    Department of Dermatology, Center for Dermatooncology, University Medical Center, Liebermeisterstrasse 25, Tubingen 72076, Germany
    Br J Cancer 107:422-8. 2012
  6. doi request reprint Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
    Benjamin Weide
    University Medical Center, University of Tubingen, Tubingen, Germany
    J Clin Oncol 30:1835-41. 2012
  7. doi request reprint High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma
    Benjamin Weide
    Department of Dermatology, Center of Dermato Oncology, University of Tuebingen, Tuebingen, Germany
    Cancer 116:4139-46. 2010
  8. ncbi request reprint Plasmid DNA- and messenger RNA-based anti-cancer vaccination
    Benjamin Weide
    Department of Dermatology, University of Tubingen, Liebermeisterstrasse 25, Tubingen, Germany
    Immunol Lett 115:33-42. 2008
  9. doi request reprint Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
    Benjamin Weide
    Department of Dermatology, Division of Dermatooncology, University of Tubingen, Tubingen, Germany
    J Immunother 32:498-507. 2009
  10. doi request reprint Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up
    Benjamin Weide
    Department of Dermatology, Center of Dermatooncology, University of Tubingen, Liebermeisterstr 25, 72076, Tubingen, Germany
    Cancer Immunol Immunother 60:487-93. 2011

Collaborators

Detail Information

Publications35

  1. doi request reprint Immunologic correlates in the course of treatment with immunomodulating antibodies
    Benjamin Weide
    Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Germany Electronic address
    Semin Oncol 42:448-58. 2015
    ..We will discuss how to prospectively validate and integrate these parameters for routine assessment of patients in daily clinical practice and give an outlook on promising future directions of biomarker research...
  2. doi request reprint Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses
    Benjamin Weide
    Authors Affiliations Departments of Dermatology, Center of Dermato Oncology and
    Cancer Immunol Res 2:668-78. 2014
    ..Finally, we recorded encouraging data about the progression time to distant metastases and overall survival...
  3. pmc Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour
    Benjamin Weide
    Center for Dermatooncology, Department of Dermatology, University Medical Center, Tuebingen, Germany
    PLoS ONE 8:e66953. 2013
    ....
  4. pmc Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis
    Benjamin Weide
    Department of Dermatology, University Medical Center, Tubingen, Germany
    PLoS ONE 8:e63137. 2013
    ....
  5. pmc Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
    B Weide
    Department of Dermatology, Center for Dermatooncology, University Medical Center, Liebermeisterstrasse 25, Tubingen 72076, Germany
    Br J Cancer 107:422-8. 2012
    ..Established prognostic factors are of limited value to predict long-term survival and benefit from metastasectomy in advanced melanoma. This study aimed to identify prognostic factors in patients with distant metastasis...
  6. doi request reprint Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
    Benjamin Weide
    University Medical Center, University of Tubingen, Tubingen, Germany
    J Clin Oncol 30:1835-41. 2012
    ..To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A, MAGE-3, and survivin in patients with melanoma with distant metastasis...
  7. doi request reprint High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma
    Benjamin Weide
    Department of Dermatology, Center of Dermato Oncology, University of Tuebingen, Tuebingen, Germany
    Cancer 116:4139-46. 2010
    ..The objectives of the current study were to confirm those results in a larger cohort and to identify patient or regimen characteristics associated with response...
  8. ncbi request reprint Plasmid DNA- and messenger RNA-based anti-cancer vaccination
    Benjamin Weide
    Department of Dermatology, University of Tubingen, Liebermeisterstrasse 25, Tubingen, Germany
    Immunol Lett 115:33-42. 2008
    ..Combining optimized MNAV formulations and parallel adjuvant treatments could allow to turn MNAV-based vaccines into efficient anti-tumor immunotherapies in humans...
  9. doi request reprint Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
    Benjamin Weide
    Department of Dermatology, Division of Dermatooncology, University of Tubingen, Tubingen, Germany
    J Immunother 32:498-507. 2009
    ....
  10. doi request reprint Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up
    Benjamin Weide
    Department of Dermatology, Center of Dermatooncology, University of Tubingen, Liebermeisterstr 25, 72076, Tubingen, Germany
    Cancer Immunol Immunother 60:487-93. 2011
    ..Furthermore, the intratumoral IL-2 treatment seemed to be associated with increased complete and partial responses in subsequent chemotherapies...
  11. doi request reprint Results of the first phase I/II clinical vaccination trial with direct injection of mRNA
    Benjamin Weide
    Department of Dermatology, Institute for Cell Biology, University of Tubingen, Germany
    J Immunother 31:180-8. 2008
    ..However, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumor immunotherapy was not shown in this study and must be evaluated in subsequent trials...
  12. doi request reprint Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies
    Ulrike Leiter
    Center of Dermato Oncology, Department of Dermatology, University of Tuebingen, Liebermeisterstr 25, 72076 Tuebingen, Germany
    Clin Dermatol 28:311-5. 2010
    ..Whereas the treatment for primary melanoma is accepted world wide, follow-up strategies for melanoma patients are discussed controversially, and so far, no international consensus has been reached...
  13. doi request reprint Melanoma staging: facts and controversies
    Andrea Forschner
    Center for Dermato Oncology, Department of Dermatology, University Hospital Tubingen, 72076 Tubingen, Germany
    Clin Dermatol 28:275-80. 2010
    ..The risk of recurrence or tumor progression is very high in stage IV patients, and their management is individualized...
  14. doi request reprint Incisional biopsy and melanoma prognosis: Facts and controversies
    Annette Pflugfelder
    Center for Dermatooncology, Department of Dermatology, University Hospital Tubingen, Liebermeisterstr 25, 72076 Tubingen, Germany
    Clin Dermatol 28:316-8. 2010
    ..Incisional biopsies of malignant melanoma do not negatively influence prognosis. Complete excision of primary melanoma is still the recommended standard of care and is a precondition for accurate histopathologic diagnosis...
  15. pmc BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy
    Diana Meckbach
    Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tubingen, Germany
    PLoS ONE 9:e89218. 2014
    ..The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial...
  16. pmc Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma
    Annette Pflugfelder
    Department of Dermatology, Center for Dermatooncology, University Hospital Tuebingen, Tuebingen, Germany
    PLoS ONE 6:e16882. 2011
    ..Based on previous promising experiences within a clinical trial involving carboplatin and paclitaxel a series of advanced metastatic melanoma patients were treated with this combination...
  17. pmc Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy
    Benjamin Weide
    Department of Dermatology, University Medical Center, Tubingen, Germany German Cancer Research Center dkfz, Heidelberg, Germany German Cancer Consortium DKTK, Heidelberg, Germany
    PLoS ONE 8:e81624. 2013
    ..This study aimed to analyse the impact of S100B, lactate dehydrogenase (LDH) and the type of treatment on survival in advanced patients receiving systemic treatment...
  18. pmc Prognosis of sentinel node staged patients with primary cutaneous melanoma
    Otmar Elsaesser
    Center for Dermatooncology, Department of Dermatology, and Central Malignant Melanoma Registry of the German Dermatological Society, Eberhard Karls University of Tuebingen, Tuebingen, Germany
    PLoS ONE 7:e29791. 2012
    ....
  19. doi request reprint A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma
    Thomas K Eigentler
    Department of Dermatology, University Medical Center, Tubingen, Germany
    Clin Cancer Res 17:7732-42. 2011
    ..5 million international units (Mio IU) IL2 equivalents. In this study, safety and clinical activity of L19-IL2 in combination with dacarbazine were assessed in patients with metastatic melanoma...
  20. doi request reprint Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma
    Henning Zelba
    Department of Internal Medicine II, Section for Transplantation Immunology and Immunohematology Department of Immunology, University of Tubingen, Tubingen
    Clin Cancer Res 20:4390-9. 2014
    ..Here, we report the ways in which the phenotypes and functions of these T cells differentially affect survival in patients preselected for NY-ESO-1 and/or Melan-A reactivity...
  21. doi request reprint Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009
    Anne F Pfeil
    Center of Dermato Oncology, Eberhard Karls University, Tuebingen, Germany
    Melanoma Res 21:228-34. 2011
    ..Patients with MUP can be classified according to AJCC, which presented as the strongest prognostic factor. From a management perspective it is important to notice that the majority of MUP were classified as stage III...
  22. doi request reprint S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma
    Sail Abusaif
    Department of Dermatology, Skin Cancer Program, Tubingen, Germany
    Melanoma Res 23:396-401. 2013
    ....
  23. doi request reprint Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival
    Ulrike Leiter
    Center for Dermato Oncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tubingen, Germany
    Ann Surg Oncol 22:4073-80. 2015
    ..However, due to the complex drainage pattern and the risk of site associated morbidity, the potential survival benefit of SLNB is controversial in head and neck (H&N) melanoma...
  24. doi request reprint Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanoma
    Kilian Wistuba-Hamprecht
    Department of Internal Medicine II, University Medical Center, Tubingen, Germany
    Int J Cancer 138:698-704. 2016
    ..Our findings suggest peripheral blood frequencies of Vδ1+ T-cells as a potential prognostic marker in melanoma. The mechanisms by which higher abundance of Vδ1+ cells are associated with poorer survival require determination. ..
  25. ncbi request reprint Imiquimod in the treatment of extensive recurrent lentigo maligna
    Anne Kamin
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University, Tuebingen, Germany
    J Am Acad Dermatol 52:51-2. 2005
    ..Clinically and histologically, a complete clearing of the lesion was observed after treatment. Topical treatment with imiquimod seems to be effective and safe in lentigo maligna...
  26. doi request reprint Increased CCL17 serum levels are associated with improved survival in advanced melanoma
    Benjamin Weide
    Department of Immunology, University of Tubingen, Tubingen, Germany
    Cancer Immunol Immunother 64:1075-82. 2015
    ..Prognostic factors of melanoma patients with distant metastases remain poorly established. This study aimed to compare the prognostic impact of putative serum biomarkers, namely S100B, YKL-40 or CCL17, in stage IV melanoma patients...
  27. pmc Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma
    Diana Meckbach
    Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tubingen, Germany
    PLoS ONE 9:e86194. 2014
    ..A potential role of the mutational status as a prognostic factor especially in this subgroup needs to be investigated in larger studies...
  28. doi request reprint Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
    Bastian Schilling
    Department of Dermatology, University Hospital, University Duisburg Essen, Essen, Germany
    Int J Cancer 133:1653-63. 2013
    ..In vitro as well as in vivo, Vemurafenib inhibits the generation of human moMDSCs. Thus, Vemurafenib decreases immunosuppression in patients with advanced melanoma, indicating its potential as part of future immunotherapies. ..
  29. doi request reprint Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib
    Andrea Forschner
    Departments of aDermatology bRadiooncology cRadiology, Eberhard Karls University of Tubingen, Tubingen, Germany
    Melanoma Res 24:512-6. 2014
    ..Caution is needed when vemurafenib is planned for patients who have undergone previous radiotherapy, and RRR of the skin and the lung have to be taken into account. ..
  30. pmc Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters
    Christopher Shipp
    Tubingen Ageing and Tumour Immunology Group, Section for Transplantation Immunology, Department of Internal Medicine II, Centre for Medical Research, University of Tubingen, Waldhornlestr 22, 72072 Tubingen, Germany
    Cell Stress Chaperones 18:145-54. 2013
    ..This study provides further evidence for the importance of hsps in melanoma and for their use as therapeutic targets and biomarkers, but larger-scale follow-up studies are required to confirm these results...
  31. ncbi request reprint Early disseminated borreliosis with multiple erythema migrans and elevated liver enzymes: case report and literature review
    Frauke Benedix
    Department of Dermatology, Eberhard Karls University Tubingen
    Acta Derm Venereol 87:418-21. 2007
    ..Dermatologists should keep in mind that early disseminated borreliosis can present with multiple erythema migrans and hepatitis...
  32. doi request reprint Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment
    Angelika Winkler
    Department of Dermatology, University Hospital Tubingen, Tubingen, Germany
    Int J Dermatol 54:419-23. 2015
    ..Self-assessment and knowledge of individual risk factors can be a reasonable strategy to detect cutaneous malignancies in an early curable stage...
  33. doi request reprint No evidence of viral genomes in whole-transcriptome sequencing of three melanoma metastases
    Magdalena Feldhahn
    Center for Bioinformatics, University of Tubingen, Tubingen, Germany Division of Dermatooncology, Department of Dermatology, University of Tubingen, Tubingen, Germany Medical Genetics, University of Tubingen, Tubingen, Germany
    Exp Dermatol 20:766-8. 2011
    ..This renders it less likely that viruses are frequently involved in melanoma induction. A larger number of melanoma transcriptome sequencings are required to rule out viruses as a relevant pathogen...
  34. doi request reprint Melanoma brain metastasis is independent of lactate dehydrogenase A expression
    Terje Sundstrøm
    Department of Biomedicine, University of Bergen, Bergen, Norway T S, H E, K O S, S H, E H, C B R, R Bj, F T Department of Clinical Medicine, University of Bergen, Bergen, Norway T S, M L J Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway T S, M L J Edinger Institute Neurological Institute, Goethe University Medical School, Frankfurt am Main, Germany P N H, M M Center for Nuclear Medicine PET, Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway K E F Department of Dermatology, University Medical Center, Tubingen, Germany B W Department of Immunology, University of Tubingen, Tubingen, Germany B W Department of Neuropathology, Institute for Pathology and Neuropathology, University of Tubingen, Tubingen, Germany R Be Department of Diagnostic and Interventional Neuroradiology, United Kingdom
    Neuro Oncol 17:1374-85. 2015
    ..However, the mechanistic importance of LDHA in melanoma is largely unknown and hitherto unexplored in brain metastasis...
  35. pmc Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells
    Daniela Beck
    Division of Dermatologic Oncology, Department of Dermatology, University of Tubingen, 72076 Tubingen, Germany
    Sci Signal 6:ra7. 2013
    ..Thus, thapsigargin or other inducers of ER stress may be useful in combination therapies to overcome vemurafenib resistance...